Brooks Laboratories's total inventories for the quarter that ended in Mar. 2026 was ₹110.2 Mil. Brooks Laboratories's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ₹55.1 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Brooks Laboratories's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ₹-0.02.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Brooks Laboratories's Days Inventory for the
three
months ended in Mar. 2026 was 40.49.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Brooks Laboratories's Inventory Turnover for the quarter that ended in Mar. 2026 was 2.25.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Brooks Laboratories's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.27.
Brooks Laboratories (BOM:533543) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Brooks Laboratories's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Brooks Laboratories's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Brooks Laboratories Total Inventories Related Terms
Brooks Laboratories Total Inventories Historical Data
* Premium members only.
The historical data trend for Brooks Laboratories's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Brooks Laboratories (BOM:533543) has a Total Inventories of ₹110.2 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Brooks Laboratories and its competitors.
Is Brooks Laboratories' Total Inventories too high?
Brooks Laboratories' current Total Inventories is ₹110.2 Mil. Overall, Brooks Laboratories has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' Total Inventories compare to ZTS and UTHR?
Brooks Laboratories' Total Inventories of ₹110.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Brooks Laboratories and its competitors. Brooks Laboratories's current Total Inventories is ₹110.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹117.81, compared to a current price of ₹77.71 — trading 34% below its estimated fair value. The current Total Inventories is ₹110.2 Mil. Brooks Laboratories' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current Total Inventories is ₹110.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brooks Laboratories (BOM:533543) Overvalued in 2026?
Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued.
The current stock price of ₹77.71 is trading 34% below its estimated GF Value™ of ₹117.81.
GuruFocus considers Brooks Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:533543:
Total Inventories: ₹110.2 Mil
GF Value™: ₹117.81 vs. price of ₹77.71 (34% below fair value)
No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
67GF Score
Get the complete analysis for BOM:533543
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533543 has been successfully added to your 
